Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany

Frank Griesinger,Maurice Pérol,Nicolas Girard,Isabelle Durand-Zaleski,Stefan Zacharias, Lise Bosquet,Martina Jänicke,Xavier Quantin,Annika Groth,Annette Fleitz,Alan Calleja,Sonya Patel,Laure Lacoin,Melinda J. Daumont,John R. Penrod,Robert Carroll,Daniela Waldenberger,Dorothée Reynaud,Michael Thomas,Christos Chouaid

Lung Cancer（2022）

引用 4|浏览16

暂无评分

摘要

•Treatments and outcomes in locally advanced/metastatic non-small cell lung cancer.•Real-world patients in France and Germany (2015–2018) without ALK/EGFR mutations.•In first-line-treated patients, >50 % received an immune checkpoint inhibitor (ICI)•Future analyses will allow evaluation of the impact of wider ICI use in first-line.

查看译文

关键词

Advanced non-small cell lung cancer,I-O Optimise,Real-world evidence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要